156 related articles for article (PubMed ID: 32463748)
21. Eligibility Criteria and Genetic Testing Results from a High-Risk Cohort for Hereditary Breast and Ovarian Cancer Syndrome in Southeastern Ontario.
Dos Santos Vidal R; Hawrysh A; Walia JS; Davey S; Feilotter H
J Mol Diagn; 2016 May; 18(3):362-369. PubMed ID: 26941049
[TBL] [Abstract][Full Text] [Related]
22. Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study.
Azzollini J; Scuvera G; Bruno E; Pasanisi P; Zaffaroni D; Calvello M; Pasini B; Ripamonti CB; Colombo M; Pensotti V; Radice P; Peissel B; Manoukian S
Eur J Intern Med; 2016 Jul; 32():65-71. PubMed ID: 27062684
[TBL] [Abstract][Full Text] [Related]
23. Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.
Flores KG; Steffen LE; McLouth CJ; Vicuña BE; Gammon A; Kohlmann W; Vigil L; Dayao ZR; Royce ME; Kinney AY
J Genet Couns; 2017 Jun; 26(3):480-490. PubMed ID: 27496122
[TBL] [Abstract][Full Text] [Related]
24. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing.
Cohen PA; Nichols CB; Schofield L; Van Der Werf S; Pachter N
Int J Gynecol Cancer; 2016 Jun; 26(5):892-7. PubMed ID: 27051053
[TBL] [Abstract][Full Text] [Related]
25. Moving into the mainstream: healthcare professionals' views of implementing treatment focussed genetic testing in breast cancer care.
Hallowell N; Wright S; Stirling D; Gourley C; Young O; Porteous M
Fam Cancer; 2019 Jul; 18(3):293-301. PubMed ID: 30689103
[TBL] [Abstract][Full Text] [Related]
26. Pre-test genetic counseling services for hereditary breast and ovarian cancer delivered by non-genetics professionals in the state of Florida.
Vadaparampil ST; Scherr CL; Cragun D; Malo TL; Pal T
Clin Genet; 2015 May; 87(5):473-7. PubMed ID: 24735105
[TBL] [Abstract][Full Text] [Related]
27. Utility of a mainstreamed genetic testing pathway in breast and ovarian cancer patients during the COVID-19 pandemic.
Benusiglio PR; Korenbaum C; Vibert R; Ezenfis J; Geoffron S; Paul C; Richard S; Byrde V; Lejeune M; Guillerm E; Basset N; Lotz JP; Chabbert-Buffet N; Gligorov J; Coulet F
Eur J Med Genet; 2020 Dec; 63(12):104098. PubMed ID: 33186762
[TBL] [Abstract][Full Text] [Related]
28. Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers.
Collins IM; Milne RL; Weideman PC; McLachlan SA; Friedlander ML; ; Hopper JL; Phillips KA
Med J Aust; 2013 Nov; 199(10):680-3. PubMed ID: 24237098
[TBL] [Abstract][Full Text] [Related]
29. Identifying Needs: a Qualitative Study of women's Experiences Regarding Rapid Genetic Testing for Hereditary Breast and Ovarian Cancer in the DNA BONus Study.
Augestad MT; Høberg-Vetti H; Bjorvatn C; Sekse RJ
J Genet Couns; 2017 Feb; 26(1):182-189. PubMed ID: 27465808
[TBL] [Abstract][Full Text] [Related]
30. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
Shaw J; Bulsara C; Cohen PA; Gryta M; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Hardcastle SJ
Patient Educ Couns; 2018 May; 101(5):938-944. PubMed ID: 29273311
[TBL] [Abstract][Full Text] [Related]
31. Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan.
Rashid MU; Muhammad N; Amin A; Loya A; Hamann U
Breast Cancer Res Treat; 2017 Jan; 161(2):191-201. PubMed ID: 27826754
[TBL] [Abstract][Full Text] [Related]
32. BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.
Marchina E; Fontana MG; Speziani M; Salvi A; Ricca G; Di Lorenzo D; Gervasi M; Caimi L; Barlati S
Oncol Rep; 2010 Dec; 24(6):1661-7. PubMed ID: 21042765
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
Riahi A; Chabouni-Bouhamed H; Kharrat M
Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
[TBL] [Abstract][Full Text] [Related]
34. Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies.
Long KC; Kauff ND
Curr Opin Oncol; 2011 Sep; 23(5):526-30. PubMed ID: 21734577
[TBL] [Abstract][Full Text] [Related]
35. Genetic testing: new challenges in the healthcare of women. Interview by Hannah Branch.
Hofmann W; Branch H
Womens Health (Lond); 2013 Nov; 9(6):513-5. PubMed ID: 24161304
[TBL] [Abstract][Full Text] [Related]
36. A Retrospective Exploration of the Impact of the 'Angelina Jolie Effect' on the Single State-Wide Familial Cancer Program in Perth, Western Australia.
Freedman R; Mountain H; Karina D; Schofield L
J Genet Couns; 2017 Feb; 26(1):52-62. PubMed ID: 27265404
[TBL] [Abstract][Full Text] [Related]
37. Improving the referral process for familial breast cancer genetic counselling: findings of three randomised controlled trials of two interventions.
Wilson BJ; Torrance N; Mollison J; Wordsworth S; Gray JR; Haites NE; Grant A; Campbell MK; Miedyzbrodzka Z; Clarke A; Watson MS; Douglas A
Health Technol Assess; 2005 Feb; 9(3):iii-iv, 1-126. PubMed ID: 15694064
[TBL] [Abstract][Full Text] [Related]
38. Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria.
Singer CF; Muhr D; Rappaport C; Tea MK; Gschwantler-Kaulich D; Fink-Retter A; Pfeiler G; Berger A; Sun P; Narod SA
Clin Genet; 2014 Jan; 85(1):72-5. PubMed ID: 23772696
[TBL] [Abstract][Full Text] [Related]
39. Breast and ovarian cancer referrals to the ACT Genetic Service: are we meeting guidelines?
Aitken L; Warwick L; Davis A
Intern Med J; 2017 Mar; 47(3):311-317. PubMed ID: 28019080
[TBL] [Abstract][Full Text] [Related]
40. Uptake of testing for germline
Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA
Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
